We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




European Nonprofit to Focus on Personalized Medicine and Diagnostics

By LabMedica International staff writers
Posted on 09 Nov 2009
A nonprofit launched in Europe will focus on promoting and harmonizing personalized medicine and implementing "high value" diagnostics across the continent.

The European Personalized Medicine Diagnostics Association (EPEMED; Nantes, France), a membership association formed in August 2009 as a not-for-profit organization, will provide a platform for harmonization in the development and implementation of value-based diagnostics across Europe, to make personalized medicine a reality. More...
Personalized Medicine refers to the use of a person's clinical, genetic, genomic, and environmental information to select more precisely and accurately treatment for each individual patient. Its aims are to improve care and lower costs.

The central goals of EPEMED are to move personalized medicine forward throughout Europe through targeted education, idea sharing, and business models. The group plans to create joint programs with other international personalized medicine organizations, and to offer opinions on policies related to the field.

EPEMED appointed experts in the field of personalized medicine and molecular diagnostics as its founding board of directors. They include executives from Ipsogen (Marseilles, France), Genzyme Genetics (Cambridge, MA, USA), the Personalized Medicine Coalition (Washington, DC, USA), Theranostics (Rockville, MD, USA), and Novartis Molecular Diagnostics (East Hanover, NJ, USA), as well as from academic and institutional researchers, other businesses, and patient advocacy groups.

"The next few years will see deep changes in medical care due to the development of breakthrough innovations in the field of molecular diagnostics that will help clinicians in better treating their patients," Alain Huriez, founder and chairman of EPEMED, said in a statement. "It is our responsibility to make sure that these innovations will be made available to European patients and as a result, to make Europe an attractive place for innovations, financial and industrial investments in the area of personalized medicine diagnostics."

Related Links:

European Personalised Medicine Diagnostics Association
Ipsogen
Genzyme Genetics
Personalized Medicine Coalition
Theranostics
Novartis Molecular Diagnostics


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.